Leukemia & Lymphoma
Volume 62, 2021 - Issue 11
Open access
5,698
Views
12
CrossRef citations to date
0
Altmetric
Original Articles
Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma
Ying C. Oua BeiGene USA, Inc, San Mateo, CA, USACorrespondence[email protected]
View further author information
, View further author information
Zhiyu Tanga BeiGene USA, Inc, San Mateo, CA, USAView further author information
, William Novotnya BeiGene USA, Inc, San Mateo, CA, USAView further author information
, Aileen Cohena BeiGene USA, Inc, San Mateo, CA, USAView further author information
, Kun Wangb Shanghai Qiangshi Information Technology Co., Ltd, Shanghai, ChinaView further author information
, Lucy Liub Shanghai Qiangshi Information Technology Co., Ltd, Shanghai, ChinaView further author information
, Yuying Gaob Shanghai Qiangshi Information Technology Co., Ltd, Shanghai, ChinaView further author information
& Srikumar Sahasranamana BeiGene USA, Inc, San Mateo, CA, USAView further author information
show all
Pages 2612-2624
|
Received 02 Mar 2021, Accepted 03 May 2021, Published online: 23 Jun 2021
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.